Impact of Intravenous Fluid Shortages on the Time to Antibiotic Administration in the Treatment of Patients with Febrile Neutropenia
Brittany Elgersma, BS, PharmD Candidate, Dr. Sarah M. Anderson, PharmD, Dr. Christine McNamara, PharmD, Dr. Bradley Beck, PharmD, BCOP
The oncology patient population is at an elevated risk for severe infections associated with increased mortality. The early recognition of fever is critical in patients with febrile neutropenia, because a fever may be the only sign of infection.1 According to the 2010 Infectious Diseases Society of America (IDSA) guidelines, febrile neutropenia is defined as an absolute neutrophil count (ANC) of ≤500 cells/mm3, with a single oral temperature of ≥101°F or a temperature of ≥100.4°F sustained over a 1-hour period.2
Thromboprophylaxis in Patients with Newly Diagnosed Multiple Myeloma Who Received Lenalidomide-Based Regimens
Serena Chew, PharmD, BCOP, Salma Afifi, PharmD, BCOP, Michelle Nadeau Nguyen, PharmD, BCPS, Man-Yee Merl, PharmD, BCOP
Venous thromboembolism (VTE) is a major complication of hematologic malignancies and is associated with significant morbidity and mortality. Patients with multiple myeloma are especially at risk for VTEs based on the underlying disease pathophysiology and the treatments used for this patient population, specifically immunomodulatory drugs (IMiDs). The risk for VTE among patients ranges from 26% to 67% for those with newly diagnosed multiple myeloma, and from 11% to 15% for patients with relapsed or refractory multiple myeloma. The use of IMiDs further increases the risk for thromboembolic complications, particularly within the first 6 months of therapy, although this risk decreases over time.
Esra Nusseibeh, PharmD, Lynn Weber, PharmD, BCOP, Katie Won, PharmD, BCOP, Shannon Reidt, PharmD, MPH
Cisplatin is a platinum-based antineoplastic drug that is widely prescribed alone or in combination for the treatment of patients with solid-organ tumors.
Shabnam Dakwala-Sheikh, PharmD, Genevieve Moore, PharmD, Leila Mohassel, PharmD, BCPS, BCOP, Casey Washington, PharmD, BCPS
Myelosuppression is a dose-limiting complication of systemic chemotherapy that can result in serious and life-threatening infections.
Effectiveness of a Single 6-mg Fixed Dose of Rasburicase for Prevention or Management of Hyperuricemia Associated with Tumor Lysis Syndrome in Adults with Cancer
Mansoor Ahmed Khan, BS, MS, BCOP, Majed A. Alshamrani, PharmD, BCPS, BCOP, Mohammed A. Aseeri, PharmD, BCPS, FISMP, Ahmad S. Al Saeed, MD, Hani S. Alhamdan, BS, MS, Ahlam O. Masari, MD
Tumor lysis syndrome (TLS) is a life-threatening complication of hematologic malignancies and some solid tumors. This syndrome occurs after tumor cells break down spontaneously or after exposure to radiation or chemotherapy. Lysis of tumor cells will release intracellular contents into the bloodstream, leading to hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.
Sterility Duration of Single-Use Vials for Antineoplastic Agents or Monoclonal Antibodies Extended with a Closed-System Transfer Device
Major Rosalynda Uy, PharmD, BCPS, Michael S. Edwards, PharmD, MBA, BCOP, FASHP, Dominic A. Solimando, Jr, MA, BCOP, FAPhA, FASHP
The use of a closed-system transfer device (CSTD) has been accepted as a standard of practice to minimize exposure to harmful materials when compounding hazardous medications. Several reports indicate that CSTDs also preserve the sterility of unpreserved (ie, single-use) medication vials for up to 1 week. Taking advantage of prolonged sterility of nonpreserved vials with an appropriate CSTD attached offers the possibility of significant cost-savings through reduced drug waste.
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Ovarian cancer is the leading cause of death among gynecologic tumors.
Pharmacists play a vital role in ensuring the safe administration of medications.
Retrospective Review of the Use of Oral Chemotherapy Drugs for Patients with Metastatic Kidney Cancer
Nathan M. Kawamura, PharmD, BCOP, Sara Griesbach , PharmD, BCPS, BCACP, Sue Wilhelm, RPh, BCPS, Richard Mercier, MD
Nathan M. Kawamura, PharmD, BCOP, and colleagues assess the reasons for dose reductions and treatment discontinuation in patients who receive oral chemotherapy for metastatic kidney cancer.
Comparing Grade 4 Neutropenia Associated with Pegfilgrastim Administered via the Onpro Device versus Manual Injection with a Prefilled Syringe
This single-institution study led by Caroline Townley, PharmD, compares the use of the Onpro device and the manual injection of pegfilgrastim and discusses the potential implications of the findings.
Page 3 of 8
Results 21 - 30 of 74
Results 21 - 30 of 74